Ameye C, Sundmacher R, de Clercq E
Universitäts-Augenklinik, Düsseldorf, Federal Republic of Germany.
Graefes Arch Clin Exp Ophthalmol. 1989;227(2):118-22. doi: 10.1007/BF02169782.
A therapeutic trial with topical bromovinyldeoxyuridine (BVDU) plus low-dosage steroids was conducted in five patients with chronic zoster keratouveitis, who had previously received topical acyclovir (ACV) and steroids. In all cases, BVDU (plus steroids) was found to be superior to ACV (plus steroids). Yet BVDU was not able to keep the patients from having chronic relapsing varicella-zoster keratouveitis. This can probably be explained by pathophysiological reasons, i.e., the persistence and low-grade multiplication of the varicella-zoster virus in peripheral eye tissues during the chronic carrier stage. It is possible that this chronic carrier status could be obviated by vigorous antiviral treatment during the acute phase of the illness.
对5例慢性带状疱疹性角膜葡萄膜炎患者进行了一项局部使用溴乙烯脱氧尿苷（BVDU）加低剂量类固醇的治疗试验，这些患者此前已接受局部阿昔洛韦（ACV）和类固醇治疗。在所有病例中，发现BVDU（加类固醇）优于ACV（加类固醇）。然而，BVDU并不能阻止患者发生慢性复发性水痘-带状疱疹性角膜葡萄膜炎。这可能可以用病理生理学原因来解释，即水痘-带状疱疹病毒在慢性携带阶段在外周眼组织中持续存在并进行低水平增殖。在疾病急性期进行积极的抗病毒治疗有可能消除这种慢性携带状态。
